Patents Controller Order On Dimminaco Vaccine Quashed

Image
BUSINESS STANDARD
Last Updated : Feb 26 2013 | 12:54 AM IST

The Calcutta High Court has quashed an order passed by the controller of patents & designs rejecting an application for patent filed by Dimminaco AG, a Swiss company.

In the patent application, the Swiss firm sought patent on an invention relating to a process for the preparation of infectious bursitis vaccine.

The application was examined by the patent office and gave a finding that what is claimed in the application does not constitute an invention under the Patent Act. The Swiss company moved in the High Court challenging the order of rejection.

Also Read

Justice Asok Kumar Ganguly, in a recent judgment, quashed the order of the controller of patents and designs passed on December 27, 1999, and directed the authority concerned to reconsider the Swiss company's application for patent.

The judge observed: "The application for patent has been refused mainly on the ground that the end-product contains a living organism. Therefore, it has been held that it cannot be called a manner of manufacture".

The court held that the examiner claimed that the specification does not constitute an invention.

But reasons for such a finding has not been given. It appears that, while giving his report, the examiner has to act in a quasi-judicial manner, and it is well settled as a proposition of law that when an authority, acting in a quasi-judicial manner, passes an order which affects the rights of the parties, it should be a reasoned one, the court observed.

The judge also held: "The controller erred himself in law by holding that merely because the end product contains a live virus, the process involved in bringing out the end product is not an invention".

Justice Ganguly in his order said: "The order passed by the controller that the claim process does not lead to the manufacture of a substance also cannot be accepted. The court observed that since the claim process for patent leads to a vendible product, it is certainly a substance after going through the process of manufacture".

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 14 2002 | 12:00 AM IST

Next Story